The ABC of ADCs (Antibody-Drug Conjugates): A Comprehensive Review of Technical, Regulatory, and Clinical Challenges
- 1 Veranova, Devens, MA, USA
Abstract
Over the past several decades, there has been a significant surge in the devel opment of Antibody-Drug Conjugates (ADCs). Designing an ideal ADC pre sents a multifaceted challenge, requiring the precise orchestration of various elements such as antigens, antibodies, linkers, and payloads. While ADCs aim to target tumor cells specifically, several antigens can also be found in regular tissues, potentially compromising the specificity of ADCs in therapeutic applications. The complexity extends to antibody selection, necessitating effective targeting of the desired antigen and ensuring compatibility with linkers for effective payload delivery. Additionally, the linker and payload combination are critical for the ADC’s therapeutic efficiency, balancing stability in circulation and timely payload release upon target binding. ADC doses must be safe for normal tissues while ensuring the released payloads are effective. The success of ADCs is attributed to their unmatched efficacy compared to traditional chemotherapy agents. The current research article aims to provide a technical review of Antibody-Drug Conjugates (ADCs) for cancer therapies. A brief discussion on the basics of ADCs, regulatory approach, overview, and technical complexities for quantification is presented. This review also summarizes recently approved ADCs and introduces the concepts of antibodies, linkers, and payloads. The article also outlines cancer-specific ADCs currently in late-stage clinical trials for cancer treatment.
- Lu, J., Jiang, F., Lu, A. and Zhang, G. (2016) Linkers Having a Crucial Role in Antibody-Drug Conjugates. International Journal of Molecular Sciences, 17, Article 561. https://doi.org/10.3390/ijms17040561
- (2016) Biooncology. http://www.biooncology.com/
- Fu, Z., Li, S., Han, S., Shi, C. and Zhang, Y. (2022) Antibody-Drug Conjugate: The “Biological Missile” for Targeted Cancer Therapy. Signal Transduction and Targeted Therapy, 7, Article No. 93. https://doi.org/10.1038/s41392-022-00947-7
- Maecker, H., Jonnalagadda, V., Bhakta, S., Jammalamadaka, V. and Junutula, J.R. (2023) Exploration of the Antibody-Drug Conjugate Clinical Landscape. mAbs, 15, Article ID: 2229101. https://doi.org/10.1080/19420862.2023.2229101
- Tong, J.T.W., Harris, P.W.R., Brimble, M.A. and Kavianinia, I. (2021) An Insight into FDA Approved Antibody-Drug Conjugates for Cancer Therapy. Molecules, 26, Article 5847. https://doi.org/10.3390/molecules26195847
- U.S. Food and Drug Administration. Guidance for Industry: Chemistry, Manufacturing, and Controls (CMC) Information for Human Gene Therapy Investigational New Drug Applications (INDs). https://www.fda.gov/media/113760/download
- Clinical Pharmacology Considerations for Antibody-Drug Conjugates. https://www.fda.gov/media/155997/download
- U.S. Food and Drug Administration. Guidance for Industry: Questions and Answers on Biosimilar Development and the BPCI Act (Revision 1). https://www.fda.gov/media/119258/download
- Bechtold-Peters, K., Ruggiero, A., Vriezen, N., Niu, S., Feng, Y. and Wang, X. (2023) CMC Regulatory Considerations for Antibody-Drug Conjugates. Journal of Pharmaceutical Sciences. https://doi.org/10.1016/j.xphs.2023.09.007
- Sasso, J.M., Tenchov, R., Bird, R., Iyer, K.A., Ralhan, K., Rodriguez, Y. and Zhou, Q.Q. (2023) The Evolving Landscape of Antibody-Drug Conjugates: In Depth Analysis of Recent Research Progress. Bioconjugate Chemistry. https://doi.org/10.1021/acs.bioconjchem.3c00374
- Jin, Y., Schladetsch, M.A., Huang, X., Balunas, M.J. and Wiemer, A.J. (2022) Stepping Forward in Antibody-Drug Conjugate Development. Pharmacology & Therapeutics, 229, Article ID: 107917. https://doi.org/10.1016/j.pharmthera.2021.107917
- Drago, J.Z., Modi, S. and Chandarlapaty, S. (2021) Unlocking the Potential of Antibody-Drug Conjugates for Cancer Therapy. Nature Reviews Clinical Oncology, 18, 327-344. https://doi.org/10.1038/s41571-021-00470-8